A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
|Videos|October 18, 2020
What keeps you up at night in ophthalmology: Part II
Author(s)Alex Delaney-Gesing
Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.
Advertisement
In this second video installment, pharmaceutical representatives share what keeps them up at night within the ophthalmic and glaucoma space while attending the 2020
Featured: Chris Adams, Diopter Corp (CEO); Daria Lemann-Blumenthal, BELKIN Laser Ltd (CEO); Victor Chan, MB, MS, director of U.S. Surgical Device Commercial Marketing (Santen, Inc); Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline (Allergan).
Advertisement
Related to this article
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5